Open-Label Tolvaptan Study in Subjects With ADPKD (TEMPO 4/4)

Conditions

Autosomal Dominant Polycystic Kidney Disease

What is the purpose of this trial?

To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from baseline (from trial 156-04-251) in total kidney volume (TKV) and renal function.


Participation Guidelines

Age:
18 Months and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Dates:
11/04/2010
Last Updated:
Study HIC#:
1008007307